UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2354-2
Program Prior Authorization/Medical Necessity
Medication Miplyffa™ (arimoclomol)
P&T Approval Date 11/2024, 1/2025
Effective Date 4/1/2025
1. Background
Miplyffa (arimoclomol) is indicated for use in combination with miglustat for the treatment of
neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric
patients 2 years of age and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Miplyffa will be approved based on all of the following criteria:
a. Both of the following:
(1) Diagnosis of Niemann-Pick disease type C (NPC)
-AND-
(2) Diagnosis has been genetically confirmed by mutation analysis of NPC1 and
NPC2 genes
-AND-
b. Miplyffa is being used to treat neurological manifestations of NPC
-AND-
c. Miplyffa is prescribed in combination with miglustat
-AND-
d. Patient is not receiving Miplyffa in combination with Aqneursa (levacetylleucine)
-AND-
e. Miplyffa is prescribed by or in consultation with a provider with expertise in the
treatment of NPC
Authorization will be issued for 12 months.
B. Reauthorization
© 2025 UnitedHealthcare Services Inc.
1
1. Miplyffa will be approved based on all of the following criteria:
a. Documentation of positive clinical response to Miplyffa therapy (e.g., slowed
disease progression from baseline based on assessment with NPC–specific scales)
-AND-
b. Miplyffa continues to be prescribed in combination with miglustat
-AND-
c. Patient is not receiving Miplyffa in combination with Aqneursa (levacetylleucine)
-AND-
d. Miplyffa is prescribed by or in consultation with a provider with expertise in the
treatment of NPC
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Miplyffa® [package insert], Lake Forest, IL: Horizon Therapeutics, Inc.; September 2021.
2. Geberhiwot T, Moro A, Dardis A, et al. Consensus clinical management guidelines for
Niemann-Pick disease type C. Orphanet J Rare Dis. 2018;13(1):50. Published 2018 Apr 6.
doi:10.1186/s13023-018-0785-7
Program Prior Authorization/Medical Necessity - Miplyffa (arimoclomol)
Change Control
11/2024 New program.
1/2025 Added criteria that Miplyffa not taken in combination with Aqneursa.
© 2025 UnitedHealthcare Services Inc.
2